- Published on
Infectious Disease and Microbiology – Brain Abscess
Brain abscess is a focal collection of purulent material within the brain parenchyma caused by bacterial, fungal, or protozoal infection. It may present as a well-formed abscess with a defined capsule or as an early inflammatory stage known as cerebritis. This is a rare condition, identified in 0.2–1.3% of large autopsy series and approximately 1 in 10,000 hospital admissions. About 25% of cases occur in children, and the median age at diagnosis is 30–45 years.
Risk factors include sinusitis, otitis media, poor dental hygiene, infective endocarditis, bacteremia from indwelling central lines or intravenous drug use, Osler–Weber–Rendu disease, preexisting brain injury, immunodeficiency, cyanotic congenital heart disease, and intrapulmonary shunting due to arteriovenous malformations. Preventive strategies involve prompt treatment of sinus and ear infections and maintaining good dental hygiene, particularly management of upper molar abscesses.
Infection reaches the brain through direct extension from adjacent structures (sinuses, middle ear, mastoid, orbit, teeth, meninges), following trauma or neurosurgery, or via hematogenous spread. The causative organisms often reflect the source. Otogenic, sinus, and odontogenic infections commonly involve mixed flora including anaerobes, microaerophilic and viridans streptococci, Streptococcus milleri, Haemophilus species, Fusobacterium, Prevotella, Enterobacteriaceae, and Pseudomonas. Post-traumatic or postoperative infections frequently involve Staphylococcus aureus, Pseudomonas, other gram-negative bacilli, and Propionibacterium. Hematogenous spread may involve S. aureus, streptococci, Salmonella, Listeria, Klebsiella pneumoniae, Escherichia coli, Proteus, Pseudomonas, Bacteroides species, Actinomyces, and fungi. In immunocompromised hosts, pathogens include Toxoplasma gondii, Listeria, Rhodococcus equi, Nocardia asteroides, Aspergillus, Cryptococcus neoformans, Coccidioides immitis, Candida, Zygomycetes, Cladosporium, and Curvularia. In immigrants from endemic areas, parasitic causes such as Taenia solium, Entamoeba histolytica, Schistosoma japonicum, and Paragonimus species should be considered.
Clinical manifestations are often subtle and nonspecific. Headache of less than two weeks’ duration occurs in approximately 75% of patients. Other symptoms include neck stiffness (25%), mental status changes, nausea, vomiting, low-grade fever (45–50%), focal neurological deficits (50%), and seizures (25%), which may prompt initial neuroimaging. Signs of increased intracranial pressure such as papilledema and third or sixth cranial nerve palsies suggest significant cerebral edema. Presentation varies depending on abscess location, pathogen, and underlying disease.
Laboratory findings may show leukocytosis in 60–70% of patients and elevated ESR in up to 90%. Lumbar puncture is generally contraindicated in patients with focal neurological signs due to risk of herniation. Blood cultures may be positive. Definitive microbiological diagnosis is achieved through stereotactic aspiration with Gram stain, culture, special stains, and increasingly 16S ribosomal RNA sequencing. Serologic testing may assist in suspected toxoplasmosis or neurocysticercosis.
Neuroimaging with CT or MRI is essential. Gadolinium-enhanced MRI provides superior visualization, especially in the brainstem, and diffusion-weighted imaging helps distinguish abscesses from neoplastic lesions. Ring-enhancing lesions may persist for several months despite adequate therapy. Serial imaging is necessary to monitor response to treatment.
Stereotactic aspiration is the procedure of choice for abscesses larger than 2.5 cm and that are surgically accessible. Craniotomy with aspiration may be required when vascular structures must be directly visualized. Differential diagnosis includes epidural or subdural empyema, septic dural sinus thrombosis, mycotic aneurysms, septic emboli with infarction, necrotizing encephalitis, primary or metastatic brain tumors, pyogenic meningitis, hematoma, and radiation necrosis.
Management requires prompt initiation of empiric intravenous antibiotics after appropriate cultures are obtained. For abscesses arising from oral, sinus, or otogenic sources, cefotaxime or ceftriaxone combined with metronidazole is recommended. Alternatively, penicillin G plus metronidazole may be used for oral sources. For suspected hematogenous spread, vancomycin combined with metronidazole and a third-generation cephalosporin is advised. Postsurgical infections should be treated with vancomycin plus ceftazidime or cefepime. If methicillin-sensitive S. aureus is identified, vancomycin should be replaced with nafcillin or oxacillin for improved CNS penetration. Therapy typically continues for 6–8 weeks or longer, guided by clinical and radiographic response. Corticosteroids may be used in cases of significant mass effect and depressed mental status. Surgical intervention is both diagnostic and therapeutic, relieving intracranial pressure and providing material for microbiologic diagnosis.
Complications include cerebral herniation (15–20%), persistent neurological deficits such as hemiparesis (up to 50%), epilepsy (fewer than 50%), and significant morbidity. Mortality is strongly influenced by neurological status at presentation. Long-term follow-up with serial CT or MRI scans for at least one year after completion of antibiotics is recommended to monitor for recurrence or residual disease.
Brain abscess is a focal collection of purulent material within the brain parenchyma caused by bacterial, fungal, or protozoal infection. It may present as a well-formed abscess with a defined capsule or as an early inflammatory stage known as cerebritis. This is a rare condition, identified in 0.2–1.3% of large autopsy series and approximately 1 in 10,000 hospital admissions. About 25% of cases occur in children, and the median age at diagnosis is 30–45 years.
Risk factors include sinusitis, otitis media, poor dental hygiene, infective endocarditis, bacteremia from indwelling central lines or intravenous drug use, Osler–Weber–Rendu disease, preexisting brain injury, immunodeficiency, cyanotic congenital heart disease, and intrapulmonary shunting due to arteriovenous malformations. Preventive strategies involve prompt treatment of sinus and ear infections and maintaining good dental hygiene, particularly management of upper molar abscesses.
Infection reaches the brain through direct extension from adjacent structures (sinuses, middle ear, mastoid, orbit, teeth, meninges), following trauma or neurosurgery, or via hematogenous spread. The causative organisms often reflect the source. Otogenic, sinus, and odontogenic infections commonly involve mixed flora including anaerobes, microaerophilic and viridans streptococci, Streptococcus milleri, Haemophilus species, Fusobacterium, Prevotella, Enterobacteriaceae, and Pseudomonas. Post-traumatic or postoperative infections frequently involve Staphylococcus aureus, Pseudomonas, other gram-negative bacilli, and Propionibacterium. Hematogenous spread may involve S. aureus, streptococci, Salmonella, Listeria, Klebsiella pneumoniae, Escherichia coli, Proteus, Pseudomonas, Bacteroides species, Actinomyces, and fungi. In immunocompromised hosts, pathogens include Toxoplasma gondii, Listeria, Rhodococcus equi, Nocardia asteroides, Aspergillus, Cryptococcus neoformans, Coccidioides immitis, Candida, Zygomycetes, Cladosporium, and Curvularia. In immigrants from endemic areas, parasitic causes such as Taenia solium, Entamoeba histolytica, Schistosoma japonicum, and Paragonimus species should be considered.
Clinical manifestations are often subtle and nonspecific. Headache of less than two weeks’ duration occurs in approximately 75% of patients. Other symptoms include neck stiffness (25%), mental status changes, nausea, vomiting, low-grade fever (45–50%), focal neurological deficits (50%), and seizures (25%), which may prompt initial neuroimaging. Signs of increased intracranial pressure such as papilledema and third or sixth cranial nerve palsies suggest significant cerebral edema. Presentation varies depending on abscess location, pathogen, and underlying disease.
Laboratory findings may show leukocytosis in 60–70% of patients and elevated ESR in up to 90%. Lumbar puncture is generally contraindicated in patients with focal neurological signs due to risk of herniation. Blood cultures may be positive. Definitive microbiological diagnosis is achieved through stereotactic aspiration with Gram stain, culture, special stains, and increasingly 16S ribosomal RNA sequencing. Serologic testing may assist in suspected toxoplasmosis or neurocysticercosis.
Neuroimaging with CT or MRI is essential. Gadolinium-enhanced MRI provides superior visualization, especially in the brainstem, and diffusion-weighted imaging helps distinguish abscesses from neoplastic lesions. Ring-enhancing lesions may persist for several months despite adequate therapy. Serial imaging is necessary to monitor response to treatment.
Stereotactic aspiration is the procedure of choice for abscesses larger than 2.5 cm and that are surgically accessible. Craniotomy with aspiration may be required when vascular structures must be directly visualized. Differential diagnosis includes epidural or subdural empyema, septic dural sinus thrombosis, mycotic aneurysms, septic emboli with infarction, necrotizing encephalitis, primary or metastatic brain tumors, pyogenic meningitis, hematoma, and radiation necrosis.
Management requires prompt initiation of empiric intravenous antibiotics after appropriate cultures are obtained. For abscesses arising from oral, sinus, or otogenic sources, cefotaxime or ceftriaxone combined with metronidazole is recommended. Alternatively, penicillin G plus metronidazole may be used for oral sources. For suspected hematogenous spread, vancomycin combined with metronidazole and a third-generation cephalosporin is advised. Postsurgical infections should be treated with vancomycin plus ceftazidime or cefepime. If methicillin-sensitive S. aureus is identified, vancomycin should be replaced with nafcillin or oxacillin for improved CNS penetration. Therapy typically continues for 6–8 weeks or longer, guided by clinical and radiographic response. Corticosteroids may be used in cases of significant mass effect and depressed mental status. Surgical intervention is both diagnostic and therapeutic, relieving intracranial pressure and providing material for microbiologic diagnosis.
Complications include cerebral herniation (15–20%), persistent neurological deficits such as hemiparesis (up to 50%), epilepsy (fewer than 50%), and significant morbidity. Mortality is strongly influenced by neurological status at presentation. Long-term follow-up with serial CT or MRI scans for at least one year after completion of antibiotics is recommended to monitor for recurrence or residual disease.
- Published on
Infectious Disease and Microbiology – Botulism
Botulism is a potentially life-threatening neuroparalytic syndrome caused by neurotoxins produced by Clostridium botulinum. Botulinum neurotoxin (BoNT) is among the most potent toxins known. There are five epidemiologic forms of botulism: foodborne, infant botulism, wound botulism, intestinal colonization (adult infectious botulism), and inhalational botulism. Symptoms typically develop 12–36 hours after ingestion of preformed toxin.
Botulism is rare but can occur in small outbreaks, often associated with commercially or home-canned foods. In the United States, most cases occur in infants, approximately one-fourth are foodborne, and a smaller number are related to wounds. Risk factors include improper home canning of low-acid foods such as corn, asparagus, beans, and beets. The fatality rate is higher among patients older than 60 years. Honey ingestion is a well-established risk factor for infant botulism due to gastrointestinal colonization and in situ toxin production. Wound botulism should be suspected in intravenous drug users. Iatrogenic cases have been reported following injection of unlicensed botulinum toxin preparations.
Prevention focuses on proper food preservation techniques. Home-canned foods should be boiled for at least 10 minutes before consumption. Infants under one year of age should not be given honey. Bulging cans should be discarded. Rapid identification of suspected cases is essential to prevent outbreaks.
C. botulinum is an anaerobic, gram-positive, spore-forming rod. It produces toxins classified from types A to G, based on antigenic differences. Human disease is most commonly associated with toxin types A, B, E, and F. Type A is frequently found in the western United States and China, type B in the eastern United States and Europe, and type F worldwide, often linked to fish products. The spores are widely present in soil and marine sediments. While spores are resistant to boiling, they can be destroyed by heating to 120°C. Because of its extreme toxicity, botulinum toxin is considered a potential biological warfare agent.
Clinically, botulism presents with bilateral cranial neuropathies followed by symmetric descending weakness. Patients typically remain afebrile, awake, and alert despite progressive paralysis. Sensory function remains intact. Early manifestations may include diplopia, ptosis, dysarthria, dysphagia, and dry mouth. As paralysis progresses, respiratory failure may occur. Clinical suspicion is critical, as early diagnosis significantly impacts outcomes.
Laboratory confirmation involves detection of toxin in serum, stool, or implicated food samples. The traditional mouse bioassay has limited sensitivity, particularly in wound botulism. However, treatment should not be delayed pending laboratory confirmation when clinical suspicion is high.
The differential diagnosis includes myasthenia gravis, Lambert–Eaton syndrome, tick paralysis, the Miller Fisher variant of Guillain–Barré syndrome, stroke, poliomyelitis, and heavy metal intoxication.
Management is primarily supportive, with close monitoring of respiratory function and mechanical ventilation if required. Equine-derived antitoxin covering toxin types A, B, and E should be administered as early as possible to neutralize circulating toxin. In cases of wound botulism, appropriate antibiotics should be given after antitoxin administration. In infants, intravenous human botulism immune globulin (BIG-IV) is recommended early in the course of illness. Patients often require prolonged rehabilitation. Even after recovery, some individuals may report persistent fatigue, weakness, dizziness, and respiratory difficulty.
Botulism is a potentially life-threatening neuroparalytic syndrome caused by neurotoxins produced by Clostridium botulinum. Botulinum neurotoxin (BoNT) is among the most potent toxins known. There are five epidemiologic forms of botulism: foodborne, infant botulism, wound botulism, intestinal colonization (adult infectious botulism), and inhalational botulism. Symptoms typically develop 12–36 hours after ingestion of preformed toxin.
Botulism is rare but can occur in small outbreaks, often associated with commercially or home-canned foods. In the United States, most cases occur in infants, approximately one-fourth are foodborne, and a smaller number are related to wounds. Risk factors include improper home canning of low-acid foods such as corn, asparagus, beans, and beets. The fatality rate is higher among patients older than 60 years. Honey ingestion is a well-established risk factor for infant botulism due to gastrointestinal colonization and in situ toxin production. Wound botulism should be suspected in intravenous drug users. Iatrogenic cases have been reported following injection of unlicensed botulinum toxin preparations.
Prevention focuses on proper food preservation techniques. Home-canned foods should be boiled for at least 10 minutes before consumption. Infants under one year of age should not be given honey. Bulging cans should be discarded. Rapid identification of suspected cases is essential to prevent outbreaks.
C. botulinum is an anaerobic, gram-positive, spore-forming rod. It produces toxins classified from types A to G, based on antigenic differences. Human disease is most commonly associated with toxin types A, B, E, and F. Type A is frequently found in the western United States and China, type B in the eastern United States and Europe, and type F worldwide, often linked to fish products. The spores are widely present in soil and marine sediments. While spores are resistant to boiling, they can be destroyed by heating to 120°C. Because of its extreme toxicity, botulinum toxin is considered a potential biological warfare agent.
Clinically, botulism presents with bilateral cranial neuropathies followed by symmetric descending weakness. Patients typically remain afebrile, awake, and alert despite progressive paralysis. Sensory function remains intact. Early manifestations may include diplopia, ptosis, dysarthria, dysphagia, and dry mouth. As paralysis progresses, respiratory failure may occur. Clinical suspicion is critical, as early diagnosis significantly impacts outcomes.
Laboratory confirmation involves detection of toxin in serum, stool, or implicated food samples. The traditional mouse bioassay has limited sensitivity, particularly in wound botulism. However, treatment should not be delayed pending laboratory confirmation when clinical suspicion is high.
The differential diagnosis includes myasthenia gravis, Lambert–Eaton syndrome, tick paralysis, the Miller Fisher variant of Guillain–Barré syndrome, stroke, poliomyelitis, and heavy metal intoxication.
Management is primarily supportive, with close monitoring of respiratory function and mechanical ventilation if required. Equine-derived antitoxin covering toxin types A, B, and E should be administered as early as possible to neutralize circulating toxin. In cases of wound botulism, appropriate antibiotics should be given after antitoxin administration. In infants, intravenous human botulism immune globulin (BIG-IV) is recommended early in the course of illness. Patients often require prolonged rehabilitation. Even after recovery, some individuals may report persistent fatigue, weakness, dizziness, and respiratory difficulty.
- Published on
Infectious Disease and Microbiology – Blepharitis and Chalazion
Blepharitis is an infection and inflammation of the eyelid margins. It may be classified as anterior (involving inflammation at the base of the eyelashes), posterior (affecting the inner portion of the eyelid and meibomian glands), or granulomatous. Chalazion, in contrast, is a painless granulomatous inflammation of a meibomian gland that produces a localized nodule within the eyelid. Blepharitis is a common condition encountered by both primary care physicians and ophthalmologists. Posterior blepharitis is frequently associated with rosacea and seborrheic dermatitis.
Risk factors include dermatologic conditions such as atopic dermatitis, with more than three-fourths of such patients demonstrating positive cultures for Staphylococcus aureus. However, a positive culture does not always indicate active infection, and clinical correlation is essential. The pathophysiology involves bacterial colonization and inflammation that alter meibomian gland secretions, contributing to gland dysfunction and chronic irritation.
The most common causative organisms are Staphylococcus species, particularly S. aureus. Numerous other pathogens have been reported, including bacteria, fungi, viruses, and parasites, although these are less common. Organisms capable of colonizing adjacent skin areas such as the scalp or nares may spread to the eyelids and contribute to infection. Blepharitis is commonly associated with rosacea and seborrheic dermatitis.
Patients typically report chronic irritation, burning sensation, mild redness, and occasional pruritus of the eyelids. Some may experience blurred vision. On physical examination, acute blepharitis may present with collections of pus and ulceration at the lid margin. Chronic blepharitis often shows misdirected or missing eyelashes, telangiectasia, and a swollen lid margin. Superficial lid involvement usually presents with hyperemia and telangiectasia. Slit-lamp examination by an ophthalmologist may assist in evaluation.
Management focuses primarily on conservative measures. Warm compresses and strict eyelid hygiene are foundational treatments. Gentle massage of the eyelids using a diluted mixture of baby shampoo and water applied with a cotton-tipped applicator helps improve meibomian gland drainage. Topical ophthalmic antibiotics such as bacitracin or erythromycin (twice to four times daily for approximately two weeks) are commonly used for staphylococcal blepharitis. Gentamicin and 1% mercuric oxide preparations may also be used. In chronic or refractory cases, cultures should be obtained, and systemic antibiotics such as dicloxacillin, quinolones, or azithromycin may be considered.
For chalazion, persistent and nontender lesions may require incision and curettage. This involves removal of inflammatory debris via conjunctival incision. If infection is absent, intralesional corticosteroid injection may be considered. In rare cases of necrotizing fasciitis involving the eyelids, urgent surgical debridement is required.
Follow-up is important for nonhealing or ulcerative eyelid lesions, as basal cell carcinoma, squamous cell carcinoma, or meibomian gland carcinoma must be excluded. Complications include the development of hordeolum (stye). An external hordeolum results from staphylococcal infection of the glands of Zeis or Moll at the eyelid margin, whereas an internal hordeolum involves suppurative infection of the meibomian glands within the tarsal plate.
Blepharitis is an infection and inflammation of the eyelid margins. It may be classified as anterior (involving inflammation at the base of the eyelashes), posterior (affecting the inner portion of the eyelid and meibomian glands), or granulomatous. Chalazion, in contrast, is a painless granulomatous inflammation of a meibomian gland that produces a localized nodule within the eyelid. Blepharitis is a common condition encountered by both primary care physicians and ophthalmologists. Posterior blepharitis is frequently associated with rosacea and seborrheic dermatitis.
Risk factors include dermatologic conditions such as atopic dermatitis, with more than three-fourths of such patients demonstrating positive cultures for Staphylococcus aureus. However, a positive culture does not always indicate active infection, and clinical correlation is essential. The pathophysiology involves bacterial colonization and inflammation that alter meibomian gland secretions, contributing to gland dysfunction and chronic irritation.
The most common causative organisms are Staphylococcus species, particularly S. aureus. Numerous other pathogens have been reported, including bacteria, fungi, viruses, and parasites, although these are less common. Organisms capable of colonizing adjacent skin areas such as the scalp or nares may spread to the eyelids and contribute to infection. Blepharitis is commonly associated with rosacea and seborrheic dermatitis.
Patients typically report chronic irritation, burning sensation, mild redness, and occasional pruritus of the eyelids. Some may experience blurred vision. On physical examination, acute blepharitis may present with collections of pus and ulceration at the lid margin. Chronic blepharitis often shows misdirected or missing eyelashes, telangiectasia, and a swollen lid margin. Superficial lid involvement usually presents with hyperemia and telangiectasia. Slit-lamp examination by an ophthalmologist may assist in evaluation.
Management focuses primarily on conservative measures. Warm compresses and strict eyelid hygiene are foundational treatments. Gentle massage of the eyelids using a diluted mixture of baby shampoo and water applied with a cotton-tipped applicator helps improve meibomian gland drainage. Topical ophthalmic antibiotics such as bacitracin or erythromycin (twice to four times daily for approximately two weeks) are commonly used for staphylococcal blepharitis. Gentamicin and 1% mercuric oxide preparations may also be used. In chronic or refractory cases, cultures should be obtained, and systemic antibiotics such as dicloxacillin, quinolones, or azithromycin may be considered.
For chalazion, persistent and nontender lesions may require incision and curettage. This involves removal of inflammatory debris via conjunctival incision. If infection is absent, intralesional corticosteroid injection may be considered. In rare cases of necrotizing fasciitis involving the eyelids, urgent surgical debridement is required.
Follow-up is important for nonhealing or ulcerative eyelid lesions, as basal cell carcinoma, squamous cell carcinoma, or meibomian gland carcinoma must be excluded. Complications include the development of hordeolum (stye). An external hordeolum results from staphylococcal infection of the glands of Zeis or Moll at the eyelid margin, whereas an internal hordeolum involves suppurative infection of the meibomian glands within the tarsal plate.
- Published on
Infectious Disease and Microbiology – Blastomycosis
Blastomycosis is an acute or chronic infection caused by Blastomyces dermatitidis, a dimorphic fungus found in soil. The organism exists as mold in the environment and converts to yeast in human tissue. The annual incidence ranges from 0.3 to 1.8 cases per 100,000 population, with up to 7.4 hospital admissions per 1 million people in endemic regions. The infection is endemic in areas near bodies of water in the southeastern United States and along the Mississippi, Ohio, and St. Lawrence River valleys. It is also found along the Mediterranean coast, in South America, Mexico, and parts of Africa. Although previously thought to affect middle-aged men more commonly, this is likely related to environmental exposure patterns rather than gender predisposition. Immunocompromised individuals are at risk for more severe disease and poorer outcomes. Prevention focuses on minimizing exposure in endemic regions, including the use of respiratory protection for individuals at occupational risk.
Infection occurs through inhalation of conidia from the environment, with potential for hematogenous dissemination to other organs. The immune system more effectively clears the conidial form; however, once inside the host, the organism converts into a broad-based budding yeast form that is less susceptible to immune clearance. Reactivation may occur in immunocompromised patients.
Clinically, blastomycosis most commonly presents as pulmonary disease. Acute pneumonia presents with fever, night sweats, productive cough, dyspnea, and pleuritic chest pain, and may be accompanied by rash. Chronic pneumonia resembles pulmonary tuberculosis, with subacute onset of fever, night sweats, weight loss, mild productive cough, and sometimes hemoptysis. Disseminated disease can involve the skin, bones, genitourinary tract, central nervous system, or other organs. Skin lesions are typically non-tender papules, nodules, or plaques that may become verrucous or ulcerated. Soft tissue swelling may occur and can form draining tracts. CNS involvement may manifest as meningitis or focal neurologic deficits.
Diagnosis relies primarily on culture and direct visualization. Serologic testing is limited due to cross-reactivity with other endemic mycoses. Urine antigen testing is available but also limited by cross-reactivity. Chest radiography may reveal masses, nodules, lobar infiltrates, or cavitary lesions; lymphadenopathy is uncommon. Culture is positive in approximately 86% of sputum samples and 92% of bronchoalveolar lavage specimens. Wet mount preparations using potassium hydroxide or calcofluor white have about 46% sensitivity. The characteristic finding is a large yeast (8–15 μm) with a single broad-based bud. Histopathology shows pyogranulomas, and fungal elements are more easily visualized with methenamine silver or periodic acid–Schiff stains. The differential diagnosis includes atypical pneumonia, lung cancer, mycobacterial disease, and squamous cell carcinoma for cutaneous lesions.
Treatment depends on severity and organ involvement. For pulmonary or disseminated non-CNS disease, amphotericin B (or a lipid/liposomal formulation) is administered for two weeks, followed by itraconazole 200 mg three times daily for three days, then 200 mg twice daily for 6–12 months. Mild to moderate disease may be treated with itraconazole alone for 6–12 months. CNS disease requires lipid/liposomal amphotericin B (3–5 mg/kg IV for 4–6 weeks), followed by at least 12 months of oral azole therapy (itraconazole, fluconazole, or voriconazole). Immunocompromised patients should receive amphotericin B followed by itraconazole for at least 12 months, and lifelong suppressive therapy may be considered. In children with mild disease, itraconazole (10 mg/kg/day) is recommended for 6–12 months; severe disease requires amphotericin followed by itraconazole. In pregnancy, amphotericin B is the treatment of choice, as azoles are contraindicated.
Patients require close monitoring for antifungal toxicity. Therapeutic drug monitoring of itraconazole is recommended after two weeks of therapy, with target levels greater than 1.0 μg/mL and less than 10 μg/mL. Liver function tests should be monitored at least every three months during azole therapy. Itraconazole should be taken with food to enhance absorption. Follow-up for approximately six months after completion of therapy is recommended due to relapse risk.
Prognosis is favorable in immunocompetent individuals, with cure rates of 90–97% when treated appropriately with amphotericin. Mortality approaches 40% in immunocompromised patients, particularly those with bone marrow transplantation or AIDS. Outcomes in pregnant women can be excellent if diagnosed early, though they are at increased risk for severe disease. Complications include respiratory failure (acute respiratory distress syndrome), CNS involvement, and relapse.
Blastomycosis is an acute or chronic infection caused by Blastomyces dermatitidis, a dimorphic fungus found in soil. The organism exists as mold in the environment and converts to yeast in human tissue. The annual incidence ranges from 0.3 to 1.8 cases per 100,000 population, with up to 7.4 hospital admissions per 1 million people in endemic regions. The infection is endemic in areas near bodies of water in the southeastern United States and along the Mississippi, Ohio, and St. Lawrence River valleys. It is also found along the Mediterranean coast, in South America, Mexico, and parts of Africa. Although previously thought to affect middle-aged men more commonly, this is likely related to environmental exposure patterns rather than gender predisposition. Immunocompromised individuals are at risk for more severe disease and poorer outcomes. Prevention focuses on minimizing exposure in endemic regions, including the use of respiratory protection for individuals at occupational risk.
Infection occurs through inhalation of conidia from the environment, with potential for hematogenous dissemination to other organs. The immune system more effectively clears the conidial form; however, once inside the host, the organism converts into a broad-based budding yeast form that is less susceptible to immune clearance. Reactivation may occur in immunocompromised patients.
Clinically, blastomycosis most commonly presents as pulmonary disease. Acute pneumonia presents with fever, night sweats, productive cough, dyspnea, and pleuritic chest pain, and may be accompanied by rash. Chronic pneumonia resembles pulmonary tuberculosis, with subacute onset of fever, night sweats, weight loss, mild productive cough, and sometimes hemoptysis. Disseminated disease can involve the skin, bones, genitourinary tract, central nervous system, or other organs. Skin lesions are typically non-tender papules, nodules, or plaques that may become verrucous or ulcerated. Soft tissue swelling may occur and can form draining tracts. CNS involvement may manifest as meningitis or focal neurologic deficits.
Diagnosis relies primarily on culture and direct visualization. Serologic testing is limited due to cross-reactivity with other endemic mycoses. Urine antigen testing is available but also limited by cross-reactivity. Chest radiography may reveal masses, nodules, lobar infiltrates, or cavitary lesions; lymphadenopathy is uncommon. Culture is positive in approximately 86% of sputum samples and 92% of bronchoalveolar lavage specimens. Wet mount preparations using potassium hydroxide or calcofluor white have about 46% sensitivity. The characteristic finding is a large yeast (8–15 μm) with a single broad-based bud. Histopathology shows pyogranulomas, and fungal elements are more easily visualized with methenamine silver or periodic acid–Schiff stains. The differential diagnosis includes atypical pneumonia, lung cancer, mycobacterial disease, and squamous cell carcinoma for cutaneous lesions.
Treatment depends on severity and organ involvement. For pulmonary or disseminated non-CNS disease, amphotericin B (or a lipid/liposomal formulation) is administered for two weeks, followed by itraconazole 200 mg three times daily for three days, then 200 mg twice daily for 6–12 months. Mild to moderate disease may be treated with itraconazole alone for 6–12 months. CNS disease requires lipid/liposomal amphotericin B (3–5 mg/kg IV for 4–6 weeks), followed by at least 12 months of oral azole therapy (itraconazole, fluconazole, or voriconazole). Immunocompromised patients should receive amphotericin B followed by itraconazole for at least 12 months, and lifelong suppressive therapy may be considered. In children with mild disease, itraconazole (10 mg/kg/day) is recommended for 6–12 months; severe disease requires amphotericin followed by itraconazole. In pregnancy, amphotericin B is the treatment of choice, as azoles are contraindicated.
Patients require close monitoring for antifungal toxicity. Therapeutic drug monitoring of itraconazole is recommended after two weeks of therapy, with target levels greater than 1.0 μg/mL and less than 10 μg/mL. Liver function tests should be monitored at least every three months during azole therapy. Itraconazole should be taken with food to enhance absorption. Follow-up for approximately six months after completion of therapy is recommended due to relapse risk.
Prognosis is favorable in immunocompetent individuals, with cure rates of 90–97% when treated appropriately with amphotericin. Mortality approaches 40% in immunocompromised patients, particularly those with bone marrow transplantation or AIDS. Outcomes in pregnant women can be excellent if diagnosed early, though they are at increased risk for severe disease. Complications include respiratory failure (acute respiratory distress syndrome), CNS involvement, and relapse.
- Published on
Infectious Disease and Microbiology – Bell’s Palsy
Bell’s palsy is defined as an acute, idiopathic, unilateral paralysis of the facial nerve (cranial nerve VII). Approximately half of all facial nerve palsies are classified as Bell’s palsy. Bilateral involvement is rare, occurring in about 0.3% of cases. Although termed “idiopathic,” viral etiologies are strongly suspected, particularly herpes simplex virus. Other infectious associations include herpes zoster (including herpes zoster oticus). Rarely, Bell’s palsy has been reported as an adverse event following immunization.
The incidence in the United States ranges from 13 to 34 cases per 100,000 persons annually. The condition most commonly affects individuals aged 20–35 years and those over 70 years of age. Males and females are equally affected. Bell’s palsy is the most common cause of seventh nerve palsy in children. Risk factors include pregnancy, diabetes mellitus, and hypertension in individuals older than 40 years. Currently, there is no known preventive measure.
Clinically, Bell’s palsy presents with acute onset over one to two days and rapid progression to partial or complete unilateral facial paralysis. Patients may experience decreased tear and saliva production on the affected side, hyperacusis (increased sensitivity to sound), dysgeusia (altered taste), and retroauricular pain. The diagnosis is primarily clinical.
The differential diagnosis is broad and includes infectious causes such as Lyme disease, HIV infection (particularly during seroconversion), otitis media, mastoiditis, tuberculosis, syphilis, infectious meningitis, rubella, tetanus, Mycoplasma infection, and enteroviral infections. Noninfectious causes include sarcoidosis, Sjögren’s syndrome, systemic lupus erythematosus, tumors (parotid gland tumors, melanoma, meningioma), cerebral aneurysm, Guillain-Barré syndrome, trauma, iatrogenic injury, and others. In cases of bilateral facial paralysis, Lyme disease and sarcoidosis should be strongly considered.
Electrodiagnostic studies such as electromyography (EMG) or electroneurography may be useful in selected cases, particularly if recovery is incomplete. Patients with a typical presentation and early recovery usually do not require further testing. Imaging with CT or MRI is indicated if the presentation is atypical, if symptoms progress slowly, or if there is no improvement within six months, to exclude intracranial or middle ear pathology. Recent evidence suggests that ultrasound measurement of the distal facial nerve diameter may help predict recovery at three months.
Early treatment significantly improves outcomes. Prednisolone should be initiated within three days of symptom onset, at a dose of 60–80 mg daily for one week, as it increases the likelihood of complete recovery at three and nine months. Antiviral therapy may be added in severe cases of facial palsy. Eye protection is essential, including artificial tears during the day and lubricating ointment at night, to prevent corneal injury. The role of surgical decompression remains controversial.
Ongoing care focuses on eye protection and psychological support. Complications include incomplete recovery in approximately one-third of patients, keratitis, corneal abrasions, and recurrence in 7–15% of cases.
Bell’s palsy is defined as an acute, idiopathic, unilateral paralysis of the facial nerve (cranial nerve VII). Approximately half of all facial nerve palsies are classified as Bell’s palsy. Bilateral involvement is rare, occurring in about 0.3% of cases. Although termed “idiopathic,” viral etiologies are strongly suspected, particularly herpes simplex virus. Other infectious associations include herpes zoster (including herpes zoster oticus). Rarely, Bell’s palsy has been reported as an adverse event following immunization.
The incidence in the United States ranges from 13 to 34 cases per 100,000 persons annually. The condition most commonly affects individuals aged 20–35 years and those over 70 years of age. Males and females are equally affected. Bell’s palsy is the most common cause of seventh nerve palsy in children. Risk factors include pregnancy, diabetes mellitus, and hypertension in individuals older than 40 years. Currently, there is no known preventive measure.
Clinically, Bell’s palsy presents with acute onset over one to two days and rapid progression to partial or complete unilateral facial paralysis. Patients may experience decreased tear and saliva production on the affected side, hyperacusis (increased sensitivity to sound), dysgeusia (altered taste), and retroauricular pain. The diagnosis is primarily clinical.
The differential diagnosis is broad and includes infectious causes such as Lyme disease, HIV infection (particularly during seroconversion), otitis media, mastoiditis, tuberculosis, syphilis, infectious meningitis, rubella, tetanus, Mycoplasma infection, and enteroviral infections. Noninfectious causes include sarcoidosis, Sjögren’s syndrome, systemic lupus erythematosus, tumors (parotid gland tumors, melanoma, meningioma), cerebral aneurysm, Guillain-Barré syndrome, trauma, iatrogenic injury, and others. In cases of bilateral facial paralysis, Lyme disease and sarcoidosis should be strongly considered.
Electrodiagnostic studies such as electromyography (EMG) or electroneurography may be useful in selected cases, particularly if recovery is incomplete. Patients with a typical presentation and early recovery usually do not require further testing. Imaging with CT or MRI is indicated if the presentation is atypical, if symptoms progress slowly, or if there is no improvement within six months, to exclude intracranial or middle ear pathology. Recent evidence suggests that ultrasound measurement of the distal facial nerve diameter may help predict recovery at three months.
Early treatment significantly improves outcomes. Prednisolone should be initiated within three days of symptom onset, at a dose of 60–80 mg daily for one week, as it increases the likelihood of complete recovery at three and nine months. Antiviral therapy may be added in severe cases of facial palsy. Eye protection is essential, including artificial tears during the day and lubricating ointment at night, to prevent corneal injury. The role of surgical decompression remains controversial.
Ongoing care focuses on eye protection and psychological support. Complications include incomplete recovery in approximately one-third of patients, keratitis, corneal abrasions, and recurrence in 7–15% of cases.
- Published on
Infectious Disease and Microbiology – Bartonellosis (Oroya Fever/Verruga Peruana)
Bartonellosis is an infection caused by Bartonella bacilliformis, transmitted by sandflies of the genus Phlebotomus. It occurs in endemic areas and presents in two distinct clinical forms. Nonimmune individuals typically develop an acute febrile illness known as Oroya fever, characterized by profound hemolytic anemia. After recovery from the acute phase, a chronic cutaneous form called verruga peruana may develop, featuring angioproliferative skin lesions that resemble those seen in bacillary angiomatosis caused by other Bartonella species.
The disease is endemic to the Andean river valleys at altitudes between 600 and 2,500 meters in Peru, Ecuador, and Colombia. Oroya fever most commonly affects tourists or visitors who lack prior immunity, whereas verruga peruana is more frequently seen in the native population. Rare imported cases have been reported outside endemic regions. Risk factors include residence in or travel to endemic areas and exposure to the sandfly vector. Prevention focuses on vector control measures such as indoor and outdoor insecticide spraying, use of insect repellents, and bed nets.
Pathophysiologically, B. bacilliformis invades erythrocytes and endothelial cells. The bacteria multiply within intracellular vacuoles inside red blood cells, which are subsequently destroyed by the reticuloendothelial system, resulting in severe hemolytic anemia. The organism is a small, gram-negative bacillus closely related to Bartonella quintana.
The incubation period of Oroya fever averages about three weeks but can extend up to 100 days. The acute illness may begin gradually with low-grade fever, malaise, headache, and anorexia, or abruptly with high fever, chills, diaphoresis, altered mental status, and rapidly progressive anemia. Patients may experience dyspnea, chest discomfort, myalgias, arthralgias, and in severe cases, delirium or coma. Anasarca indicates a poor prognosis. During the convalescent phase, fever subsides and anemia improves.
Physical examination in Oroya fever reveals high fever, signs of profound anemia, generalized nontender lymphadenopathy, and occasionally thrombocytopenic purpura. Splenomegaly is uncommon and may suggest concurrent infection.
Verruga peruana develops weeks to months after recovery from the acute phase. Lesions appear in crops and may be miliary (1–4 mm papular erythematous lesions), nodular, or larger “mular” lesions exceeding 5 mm in diameter. They are typically bright red, bleed easily, and may involve skin, mucous membranes, or internal organs. Lesions are generally nontender unless secondarily infected and may be present at different stages simultaneously.
Diagnosis in the acute phase is made by identifying numerous bacteria attached to red blood cells on Giemsa- or Wright-stained peripheral blood smears or by positive blood or bone marrow cultures. Peripheral smear may also reveal macrocytosis, poikilocytosis, Howell–Jolly bodies, nucleated red blood cells, and immature myeloid cells. Profound anemia with a negative Coombs’ test is typical. In subacute cases, smears may initially be negative, and blood cultures are required. In the chronic phase, organisms can be demonstrated in cultures from skin lesions or bone marrow. Serologic tests such as ELISA or indirect immunofluorescence can support the diagnosis. Skin biopsy may show increased angiogenesis and characteristic endothelial inclusions (Rocha-Lima inclusions).
The acute phase must be differentiated from other endemic febrile illnesses such as malaria, typhoid fever, and leptospirosis. Verruga lesions resemble bacillary angiomatosis, Kaposi’s sarcoma, and certain neoplasms; epidemiologic context is a key diagnostic clue.
Treatment of Oroya fever consists of chloramphenicol (500 mg orally or intravenously every 6 hours) combined with a second antimicrobial, preferably a beta-lactam such as penicillin, for 14 days. Chloramphenicol also provides coverage against salmonellosis, a common secondary infection. Doxycycline is an alternative agent, while fluoroquinolones are generally not recommended due to resistance. Verruga peruana is treated with rifampin (10 mg/kg daily, maximum 600 mg daily) for 10–14 days. Streptomycin is a second-line option. Supportive care, including blood transfusion for severe anemia, is essential in the acute phase. Large or secondarily infected skin lesions may require surgical excision.
Patients with Oroya fever typically require inpatient management, whereas those with verruga peruana can often be managed as outpatients. Monitoring during the acute phase should include hydration status, complete blood counts, and surveillance for secondary infections such as salmonellosis, malaria, or tuberculosis.
Untreated Oroya fever carries a mortality rate of 50–88%. With appropriate therapy, fever usually resolves within 24 hours, though bacteremia may persist longer. Complications include secondary bacterial infections during convalescence and ulceration or bleeding of verruga lesions.
Bartonellosis is an infection caused by Bartonella bacilliformis, transmitted by sandflies of the genus Phlebotomus. It occurs in endemic areas and presents in two distinct clinical forms. Nonimmune individuals typically develop an acute febrile illness known as Oroya fever, characterized by profound hemolytic anemia. After recovery from the acute phase, a chronic cutaneous form called verruga peruana may develop, featuring angioproliferative skin lesions that resemble those seen in bacillary angiomatosis caused by other Bartonella species.
The disease is endemic to the Andean river valleys at altitudes between 600 and 2,500 meters in Peru, Ecuador, and Colombia. Oroya fever most commonly affects tourists or visitors who lack prior immunity, whereas verruga peruana is more frequently seen in the native population. Rare imported cases have been reported outside endemic regions. Risk factors include residence in or travel to endemic areas and exposure to the sandfly vector. Prevention focuses on vector control measures such as indoor and outdoor insecticide spraying, use of insect repellents, and bed nets.
Pathophysiologically, B. bacilliformis invades erythrocytes and endothelial cells. The bacteria multiply within intracellular vacuoles inside red blood cells, which are subsequently destroyed by the reticuloendothelial system, resulting in severe hemolytic anemia. The organism is a small, gram-negative bacillus closely related to Bartonella quintana.
The incubation period of Oroya fever averages about three weeks but can extend up to 100 days. The acute illness may begin gradually with low-grade fever, malaise, headache, and anorexia, or abruptly with high fever, chills, diaphoresis, altered mental status, and rapidly progressive anemia. Patients may experience dyspnea, chest discomfort, myalgias, arthralgias, and in severe cases, delirium or coma. Anasarca indicates a poor prognosis. During the convalescent phase, fever subsides and anemia improves.
Physical examination in Oroya fever reveals high fever, signs of profound anemia, generalized nontender lymphadenopathy, and occasionally thrombocytopenic purpura. Splenomegaly is uncommon and may suggest concurrent infection.
Verruga peruana develops weeks to months after recovery from the acute phase. Lesions appear in crops and may be miliary (1–4 mm papular erythematous lesions), nodular, or larger “mular” lesions exceeding 5 mm in diameter. They are typically bright red, bleed easily, and may involve skin, mucous membranes, or internal organs. Lesions are generally nontender unless secondarily infected and may be present at different stages simultaneously.
Diagnosis in the acute phase is made by identifying numerous bacteria attached to red blood cells on Giemsa- or Wright-stained peripheral blood smears or by positive blood or bone marrow cultures. Peripheral smear may also reveal macrocytosis, poikilocytosis, Howell–Jolly bodies, nucleated red blood cells, and immature myeloid cells. Profound anemia with a negative Coombs’ test is typical. In subacute cases, smears may initially be negative, and blood cultures are required. In the chronic phase, organisms can be demonstrated in cultures from skin lesions or bone marrow. Serologic tests such as ELISA or indirect immunofluorescence can support the diagnosis. Skin biopsy may show increased angiogenesis and characteristic endothelial inclusions (Rocha-Lima inclusions).
The acute phase must be differentiated from other endemic febrile illnesses such as malaria, typhoid fever, and leptospirosis. Verruga lesions resemble bacillary angiomatosis, Kaposi’s sarcoma, and certain neoplasms; epidemiologic context is a key diagnostic clue.
Treatment of Oroya fever consists of chloramphenicol (500 mg orally or intravenously every 6 hours) combined with a second antimicrobial, preferably a beta-lactam such as penicillin, for 14 days. Chloramphenicol also provides coverage against salmonellosis, a common secondary infection. Doxycycline is an alternative agent, while fluoroquinolones are generally not recommended due to resistance. Verruga peruana is treated with rifampin (10 mg/kg daily, maximum 600 mg daily) for 10–14 days. Streptomycin is a second-line option. Supportive care, including blood transfusion for severe anemia, is essential in the acute phase. Large or secondarily infected skin lesions may require surgical excision.
Patients with Oroya fever typically require inpatient management, whereas those with verruga peruana can often be managed as outpatients. Monitoring during the acute phase should include hydration status, complete blood counts, and surveillance for secondary infections such as salmonellosis, malaria, or tuberculosis.
Untreated Oroya fever carries a mortality rate of 50–88%. With appropriate therapy, fever usually resolves within 24 hours, though bacteremia may persist longer. Complications include secondary bacterial infections during convalescence and ulceration or bleeding of verruga lesions.
- Published on
Infectious Disease and Microbiology – Balanitis
Balanitis refers to inflammation and/or infection of the glans penis, while balanoposthitis involves both the glans and the foreskin. Infectious causes are common and may result from fungal, bacterial, viral, or parasitic pathogens. Sexual exposure plays an important role in transmission, particularly in men whose partners have Candida vaginitis. In young boys, balanitis may occur in association with diaper dermatitis.
Risk factors include being uncircumcised, diabetes mellitus (especially newly diagnosed diabetes), immunodeficiency, poor hygiene, use of broad-spectrum antibiotics, and increasing age in the case of Candida colonization. Circumcision and proper genital hygiene significantly reduce the risk. Treatment of sexual partners is important when Candida or Trichomonas infection is identified.
Infectious etiologies include Candida species (most common), Trichomonas species, anaerobic bacteria such as Bacteroides and Gardnerella vaginalis, Chlamydia, Neisseria gonorrhoeae, human papillomavirus (HPV), herpes simplex virus (HSV), Treponema pallidum, Mycoplasma, Mycobacterium (including Bacillus Calmette–Guérin), group A and B streptococci, Staphylococcus aureus, Borrelia burgdorferi, and Entamoeba histolytica.
Patients typically present with pain, tenderness, erythema, pruritus, edema, erosions, and sometimes pustules on the glans penis. Anaerobic infections may produce a characteristic foul odor.
Diagnosis is largely clinical but may be supported by laboratory testing. Fungal preparations often reveal Candida. Direct impression onto CHROMagar Candida medium has been shown to provide a higher yield than swab sampling. Wet mount examination may detect Trichomonas or Gardnerella. Urethral discharge should be tested for sexually transmitted infections. Serologic or culture testing for HIV, HPV, and HSV may be indicated based on risk factors. Blood glucose testing is recommended to evaluate for underlying diabetes mellitus.
The differential diagnosis includes numerous noninfectious conditions such as irritant dermatitis, trauma, contact dermatitis, lichen sclerosus, lichen planus, Zoon’s balanitis, erythroplasia of Queyrat, pemphigus, pemphigoid, Bowen’s disease, leukoplakia, fixed drug eruption, psoriasis (particularly inverse psoriasis), Paget’s disease, nummular eczema, scabies, and squamous cell carcinoma.
Management begins with good hygiene, including gentle washing of the glans after foreskin retraction. Candida balanitis is typically treated with topical imidazole antifungal agents, and 1% hydrocortisone cream may be added for symptomatic relief. Severe cases may require oral fluconazole. Trichomonas infection responds to metronidazole, and sexual partners should be treated simultaneously. Anaerobic infections may be managed with oral metronidazole, oral amoxicillin–clavulanate, or topical clindamycin cream.
Patients should be monitored for recurrence and evaluated for underlying diabetes if not previously diagnosed. Complications include phimosis, paraphimosis, fissuring of the prepuce, and scarring.
Balanitis refers to inflammation and/or infection of the glans penis, while balanoposthitis involves both the glans and the foreskin. Infectious causes are common and may result from fungal, bacterial, viral, or parasitic pathogens. Sexual exposure plays an important role in transmission, particularly in men whose partners have Candida vaginitis. In young boys, balanitis may occur in association with diaper dermatitis.
Risk factors include being uncircumcised, diabetes mellitus (especially newly diagnosed diabetes), immunodeficiency, poor hygiene, use of broad-spectrum antibiotics, and increasing age in the case of Candida colonization. Circumcision and proper genital hygiene significantly reduce the risk. Treatment of sexual partners is important when Candida or Trichomonas infection is identified.
Infectious etiologies include Candida species (most common), Trichomonas species, anaerobic bacteria such as Bacteroides and Gardnerella vaginalis, Chlamydia, Neisseria gonorrhoeae, human papillomavirus (HPV), herpes simplex virus (HSV), Treponema pallidum, Mycoplasma, Mycobacterium (including Bacillus Calmette–Guérin), group A and B streptococci, Staphylococcus aureus, Borrelia burgdorferi, and Entamoeba histolytica.
Patients typically present with pain, tenderness, erythema, pruritus, edema, erosions, and sometimes pustules on the glans penis. Anaerobic infections may produce a characteristic foul odor.
Diagnosis is largely clinical but may be supported by laboratory testing. Fungal preparations often reveal Candida. Direct impression onto CHROMagar Candida medium has been shown to provide a higher yield than swab sampling. Wet mount examination may detect Trichomonas or Gardnerella. Urethral discharge should be tested for sexually transmitted infections. Serologic or culture testing for HIV, HPV, and HSV may be indicated based on risk factors. Blood glucose testing is recommended to evaluate for underlying diabetes mellitus.
The differential diagnosis includes numerous noninfectious conditions such as irritant dermatitis, trauma, contact dermatitis, lichen sclerosus, lichen planus, Zoon’s balanitis, erythroplasia of Queyrat, pemphigus, pemphigoid, Bowen’s disease, leukoplakia, fixed drug eruption, psoriasis (particularly inverse psoriasis), Paget’s disease, nummular eczema, scabies, and squamous cell carcinoma.
Management begins with good hygiene, including gentle washing of the glans after foreskin retraction. Candida balanitis is typically treated with topical imidazole antifungal agents, and 1% hydrocortisone cream may be added for symptomatic relief. Severe cases may require oral fluconazole. Trichomonas infection responds to metronidazole, and sexual partners should be treated simultaneously. Anaerobic infections may be managed with oral metronidazole, oral amoxicillin–clavulanate, or topical clindamycin cream.
Patients should be monitored for recurrence and evaluated for underlying diabetes if not previously diagnosed. Complications include phimosis, paraphimosis, fissuring of the prepuce, and scarring.
- Published on
Emergency And Acute Medicine – Pneumonia in Pediatric Patients
Pneumonia in children is an infection of the lung parenchyma most commonly resulting from oropharyngeal aspiration, although hematogenous spread may occur. The radiographic distribution often depends on the organism involved: interstitial patterns are typically seen with viral infections and Mycoplasma pneumoniae, lobar consolidation with Streptococcus pneumoniae, abscess formation with Staphylococcus aureus, and diffuse disease with Pneumocystis jirovecii. Clinical presentation and likely pathogens vary significantly with age.
In neonates younger than 2 weeks, common pathogens include group B Streptococcus, enteric gram-negative organisms, respiratory syncytial virus (RSV), herpes simplex virus, and S. aureus. Between 2 weeks and 3 months, pathogens include Chlamydia trachomatis, parainfluenza virus, RSV, S. pneumoniae, S. aureus, Haemophilus influenzae, and Bordetella pertussis. From 3 months to 8 years, viral etiologies predominate (RSV, parainfluenza, influenza, adenovirus), along with S. pneumoniae, H. influenzae in unimmunized children, group A streptococcus, S. aureus, and B. pertussis. In children older than 8 years, Mycoplasma pneumoniae is most common, followed by viral pathogens and S. pneumoniae. Recent immigrants may be at risk for Mycobacterium tuberculosis. Immunocompromised children are susceptible to organisms such as Pneumocystis jirovecii, Mycobacterium avium complex, M. tuberculosis, Klebsiella pneumoniae, and Pseudomonas aeruginosa. Less common causes include fungal infections and rickettsial organisms.
Common symptoms across all pediatric age groups include cough, fever, tachypnea, tachycardia, hypoxia, rales, and signs of respiratory distress such as retractions or grunting. A maculopapular rash may occur in up to 10% of cases. Infants younger than 6 months may present atypically with irritability, lethargy, apnea (especially RSV in premature infants), cyanosis, poor feeding, temperature instability, vomiting with coughing, nasal congestion, nasal flaring, or wheezing. A staccato cough in infants suggests Chlamydia trachomatis. Older children, particularly those over 5 years, are more likely to report pleuritic chest pain, productive cough, rigors, and chills. A thorough history should include immunization status, immune function, exposures, and progression of symptoms.
Pulse oximetry is essential in all suspected cases. Chest radiography remains the gold standard for diagnosis and should be obtained in children with signs of lower respiratory tract infection and in those younger than 36 months with marked leukocytosis (WBC >15,000 or absolute neutrophil count >9,000). Viral and Mycoplasma infections often produce interstitial, perihilar, or peribronchial infiltrates, whereas bacterial infections may demonstrate focal lobar consolidation, alveolar infiltrates, pleural effusion, or pneumatocele. Round pneumonia is considered pathognomonic for S. pneumoniae. Lateral decubitus films can help identify pleural effusions.
Laboratory studies may include a complete blood count, although sensitivity and specificity are limited. Marked leukocytosis (WBC ≥20,000 or ANC >9,000) increases the risk of pneumococcal bacteremia. Bordetella pertussis typically presents with leukocytosis and lymphocytosis. Blood cultures are recommended in children younger than 36 months and in toxic-appearing or hospitalized patients, though yield is low. Arterial blood gas analysis may be necessary in critically ill patients to assess respiratory insufficiency. Electrolytes should be checked in hypotensive children or when syndrome of inappropriate antidiuretic hormone secretion is suspected. Sputum cultures may be obtained in older children, and nasopharyngeal testing can identify RSV, C. trachomatis, and B. pertussis.
Initial management focuses on airway, breathing, and circulation. Children with moderate to severe illness may require aggressive airway management and intubation. High-flow oxygen should be administered for hypoxia. Intravenous fluid resuscitation with 0.9% normal saline (20 mL/kg bolus) is indicated for hypovolemia or shock. Bedside glucose should be checked in severely ill infants and toddlers, with prompt treatment of hypoglycemia. Ongoing monitoring with pulse oximetry is essential.
Empiric antibiotic therapy depends on age and clinical severity. Most well-appearing children aged 6 months and older can be treated as outpatients with oral antibiotics. For children aged 3 months to 5 years, amoxicillin is first-line therapy, with alternatives including amoxicillin–clavulanate or macrolides when atypical pathogens are suspected. For children aged 5 to 18 years, macrolides such as azithromycin or clarithromycin are commonly used for suspected Mycoplasma pneumoniae. Neonates requiring hospitalization should receive ampicillin plus cefotaxime or gentamicin, with azithromycin added if Chlamydia trachomatis or Bordetella pertussis is suspected. Infants 1–2 months old should receive ampicillin plus cefotaxime. Children older than 3 months requiring admission may receive cefotaxime, cefuroxime, or ceftriaxone, with vancomycin added for suspected penicillin-resistant S. pneumoniae, macrolides for atypical pathogens, and clindamycin for suspected group A streptococcal infection. Bronchodilators such as albuterol may be beneficial in children with concurrent reactive airway disease. Thoracentesis is indicated for significant pleural effusion.
Admission is warranted for toxic appearance, respiratory distress or failure, dehydration, apnea, infants younger than 2 months, infants younger than 6 months with lobar pneumonia, hypoxia (oxygen saturation <92% on room air at sea level), pleural effusion, poor outpatient response, immunocompromised status, or concerns about caregiver reliability. most mild cases can be discharged if there is no hypoxia, significant work of breathing, dehydration, vomiting, compliance concern, with follow-up ensured within 1–2 days.< />pan>
Early recognition and aggressive airway management are critical in children with severe sepsis or septic shock. Delays in antibiotic therapy should be avoided. Knowledge of local antimicrobial resistance patterns is essential to guide empiric therapy. Clear discharge instructions, reliable follow-up, and caregiver education are vital to ensure safe outpatient management.
- Published on
Emergency And Acute Medicine – Poisoning, Antidotes
Antidote therapy is used in specific toxicologic emergencies and should be administered in conjunction with supportive care and consultation with a poison control center or medical toxicologist when appropriate.
N-acetylcysteine (NAC) is indicated for acetaminophen overdose. It is most effective when given within the first 8 hours after ingestion. Common adverse effects include unpleasant odor, nausea, and vomiting. Oral dosing consists of 140 mg/kg followed by 70 mg/kg every 4 hours for 17 doses. Intravenous dosing includes 150 mg/kg in 200 mL D5W over 60 minutes, then 50 mg/kg in 500 mL D5W over 4 hours, followed by 100 mg/kg in 1,000 mL D5W over 16 hours. In pediatric patients, IV fluid volumes must be reduced to avoid fluid overload and hyponatremia.
Atropine is used for bradycardia due to drugs and for organophosphate insecticide poisoning. Caution is advised in myasthenia gravis, narrow-angle glaucoma, hypertension, coronary ischemia, and urinary obstruction. Adult dose is 1–2 mg IV. Pediatric dose is 0.02 mg/kg IV (minimum 0.1 mg). Large repeated doses may be required in organophosphate poisoning.
Benztropine (Cogentin) is indicated for acute dystonic reactions. It should be used cautiously in carbamate exposure, myasthenia gravis, narrow-angle glaucoma, hypertension, coronary ischemia, and urinary obstruction. Adult dosing is 1–2 mg IV for acute reactions or orally for prevention. Pediatric dose is 0.02 mg/kg IV or PO.
Benzodiazepines are indicated for agitation, stimulant toxicity, and seizures. Respiratory and CNS depression are potential adverse effects. Midazolam dosing is 1 mg IV or IM every 2–3 minutes as needed in adults, and 0.1 mg/kg IV or IM in children. Diazepam dosing is 2–5 mg IV or IM in adults (repeat in 10–15 minutes) and 0.1 mg/kg IV or IM in pediatrics.
Sodium bicarbonate is used for tricyclic antidepressant poisoning, metabolic acidosis, and urinary alkalinization. Adverse effects include congestive heart failure, excessive alkalosis, and hypokalemia. For serum alkalinization, give 1 mEq/kg IV push. For urine alkalinization, administer 100–150 mEq in 1 L D5W at 2–3 mL/kg/hour IV with a urine pH goal of 7–8.
Black widow spider antivenin (Latrodectus mactans) is indicated for severe hypertension and muscle spasms not relieved by analgesics and muscle relaxants, and may be considered in young children, elderly patients, and pregnant women with threatened abortion. It is equine-derived and may cause immediate hypersensitivity or delayed serum sickness. Dose is 1–2 vials IM or slow IV over 15–30 minutes; dilute one vial in 50 mL saline for IV use.
Botulinum antitoxin (trivalent A, B, E) is indicated in clinical botulism before onset of paralysis. It binds only free toxin and is not used for infant botulism. It is equine-derived with risk of hypersensitivity. Administer 1–2 vials IV every 4 hours for 4–5 doses after reconstitution.
Calcium is indicated for hyperkalemia with cardiac toxicity, hydrofluoric acid burns, calcium channel blocker overdose, and citrate, oxalate, or phosphate poisoning. Avoid in digoxin toxicity and hypercalcemia. Adult dose is 5–10 mL of 10% calcium chloride or 10–20 mL of 10% calcium gluconate IV. Pediatric dose is 0.1–0.2 mL/kg of 10% calcium chloride or 0.2–0.3 mL/kg of 10% calcium gluconate IV.
Calcium EDTA is used for lead and certain heavy metal toxicities. It may cause nephrotoxicity and other adverse effects. Dose is 1 g/m²/day IV over 8–12 hours for 5 days, with repeat cycles guided by blood lead levels.
Cyanide poisoning can be treated with a cyanide antidote kit or hydroxocobalamin. The cyanide kit includes amyl nitrite (inhaled until IV access is established), sodium nitrite (300 mg IV in adults; 0.3 mL/kg of 3% solution in children), and sodium thiosulfate (12.5 g IV in adults; 50 mg/kg in children). Hydroxocobalamin is given as 5 g IV over 15 minutes in adults, repeatable once; suggested pediatric dose is 70 mg/kg IV.
Dantrolene is indicated for malignant hyperthermia, neuroleptic malignant syndrome, serotonin syndrome, and severe muscle rigidity. Dose is 1–2 mg/kg IV bolus, repeated every 10–15 minutes as needed, maximum 10 mg/kg.
Deferoxamine treats iron toxicity. It should not be used for more than 24 hours due to risk of delayed ARDS. Dose is 10–15 mg/kg/hour IV, increased in severe cases.
Digoxin-specific antibody fragments (Digibind) are used in digoxin or digitoxin toxicity. One vial (40 mg) binds 0.6 mg digoxin. Dose estimation is based on serum level and patient weight, with typical dosing of 10–20 vials in acute overdose and 4–6 vials in chronic toxicity.
Dimercaprol (BAL) is indicated for arsenic, gold, mercury, and severe lead toxicity with encephalopathy. Dose is 3 mg/kg IM every 4 hours for 2 days, then every 12 hours for 7 days.
Flumazenil reverses benzodiazepine effects but is contraindicated in tricyclic antidepressant overdose and may precipitate seizures or withdrawal. Adult dose is 0.2 mg IV slow push, repeated every 2–3 minutes up to 1 mg. Pediatric dose is 0.01–0.05 mg/kg IV.
Fomepizole is used for methanol and ethylene glycol toxicity. Dose is 15 mg/kg IV loading, then 10 mg/kg every 12 hours for four doses, then 15 mg/kg every 12 hours thereafter.
Glucagon is used for β-blocker or calcium channel blocker overdose with bradycardia or hypotension. Adult dose is 5–10 mg IV over 1 minute; pediatric dose is 0.15 mg/kg IV.
High-dose insulin with glucose is used in severe calcium channel blocker overdose or hyperkalemia refractory to other therapy. Close glucose monitoring is required.
Naloxone (Narcan) reverses opioid toxicity. Adult dose is 0.4–2 mg IV or IM, repeat up to 10 mg. Pediatric dose is 0.1 mg/kg IV or IM. Acute withdrawal and agitation may occur.
Octreotide treats sulfonylurea-induced hypoglycemia. Adult dose is 50 micrograms subcutaneously every 6 hours. Pediatric dose is 4–5 micrograms/kg/day divided every 6 hours.
Pralidoxime (2-PAM) is used in organophosphate toxicity in conjunction with atropine. Adult dose is 1–2 g IV over 15 minutes, repeat as needed. Pediatric dose is 25–50 mg/kg over 15 minutes.
Protamine reverses heparin anticoagulation. Dose is 1 mg per 100 IU of heparin administered, given slowly IV.
Pyridoxine (vitamin B6) is used for isoniazid-induced seizures. If ingestion amount is unknown, give 5 g IV in adults or 1 g in children.
Vitamin K (phytonadione) reverses warfarin anticoagulation. Dose ranges from 2–10 mg PO or slow IV, repeat as needed based on INR.
Hyperbaric oxygen is indicated for severe carbon monoxide poisoning.
Many antivenins, including those for coral snake and rattlesnake envenomation, are animal-derived and carry risk of hypersensitivity and serum sickness. Premedication and close monitoring are required.
Antidote therapy should always accompany appropriate supportive care, monitoring, and consultation with poison control.
- Published on
Emergency And Acute Medicine – Pneumothorax
Pneumothorax is defined as the presence of free air within the intrapleural space. Spontaneous pneumothorax occurs due to atraumatic rupture of an alveolus, bronchiole, or subpleural bleb. Primary spontaneous pneumothorax accounts for approximately two-thirds of cases and occurs in patients without known underlying lung disease, typically young, tall, thin individuals aged 20–40 years. Risk factors include smoking, family history, Marfan syndrome, homocystinuria, and thoracic endometriosis. Secondary spontaneous pneumothorax occurs in the presence of underlying pulmonary pathology. Tension pneumothorax is a life-threatening form in which air enters the pleural space and becomes trapped through a “ball-valve” mechanism, leading to increased intrapleural pressure, decreased venous return, reduced cardiac output, mediastinal shift, ventilation–perfusion mismatch, and hypoxemia.
Secondary pneumothorax may result from airway diseases such as chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis; infections including necrotizing bacterial pneumonia, tuberculosis, fungal pneumonia, and Pneumocystis jirovecii infection; neoplasms; interstitial lung diseases such as sarcoidosis and idiopathic pulmonary fibrosis; lymphangiomyomatosis; tuberous sclerosis; pneumoconioses; connective tissue diseases; pulmonary infarction; endometriosis; blunt or penetrating chest trauma; and iatrogenic causes such as central line placement or other vascular access procedures.
Symptoms typically correlate with the size of the pneumothorax. Patients often present with sudden-onset, sharp, pleuritic chest pain on the affected side and shortness of breath. Some may report a dull ache in delayed presentations. Cough, malaise, or minimal symptoms may occur in small pneumothoraces. On examination, patients may have tachypnea and asymmetric decreased breath sounds with hyperresonance to percussion on the affected side. Simple spontaneous pneumothoraces usually have heart rates under 120 bpm. In tension pneumothorax, findings may include hypotension, tachycardia greater than 120 bpm, diaphoresis, cyanosis, jugular venous distention, tracheal deviation away from the affected side, and cardiovascular collapse.
Imaging is central to diagnosis. However, in hemodynamically unstable patients with strong clinical suspicion of tension pneumothorax, chest decompression must not be delayed for imaging. Upright chest radiography is the standard initial test and demonstrates absence of lung markings beyond a visible visceral pleural line. Additional findings may include mediastinal shift, the deep sulcus sign (particularly in supine trauma patients), inversion of the diaphragm, or displacement of the anterior junction line. Expiratory films do not significantly increase diagnostic yield. Chest CT is highly sensitive for small pneumothoraces but is rarely necessary for routine diagnosis. Point-of-care ultrasound is increasingly used; absence of lung sliding and comet-tail artifacts, along with characteristic M-mode findings, strongly suggests pneumothorax and may be more sensitive than chest radiography in experienced hands. ECG may show nonspecific changes and is often obtained to exclude cardiac causes of chest pain.
Initial stabilization includes cardiac monitoring, pulse oximetry, 100% oxygen via nonrebreather mask, and intravenous access. Unstable patients with suspected tension pneumothorax require immediate needle thoracostomy followed by tube thoracostomy. Needle decompression is performed using a 14–18 gauge angiocatheter in the second intercostal space at the midclavicular line or the fourth or fifth intercostal space at the anterior axillary line. Standard angiocatheters may be too short in larger patients; longer catheters may be required.
Management depends on size and clinical stability. Small primary spontaneous pneumothoraces with less than 15% lung collapse and no respiratory or cardiovascular compromise may be observed with 100% oxygen for 4–6 hours, followed by repeat chest radiography. Simple aspiration using an 8F catheter with a three-way stopcock may be attempted for 15–30% collapse or enlarging small pneumothoraces. Air is aspirated until resistance is met or up to 3 liters have been removed. If imaging confirms resolution, the catheter can be removed and the patient discharged with follow-up. A second aspiration may be attempted if the first fails. A Heimlich valve may be used for persistent but stable pneumothoraces with less than 30% collapse after failed aspiration. Suction at 20 cm H₂O may be applied if necessary.
Tube thoracostomy is indicated for tension pneumothorax, traumatic pneumothorax, pneumothorax in patients requiring positive-pressure ventilation, pneumothorax with greater than 30% collapse, most secondary pneumothoraces, or definitive management after needle decompression. Small-caliber tubes (7–14F) are appropriate for primary spontaneous pneumothorax, whereas larger tubes (20–28F) are used for secondary pneumothorax or when pleural fluid or mechanical ventilation is anticipated. All side holes must remain within the thoracic cavity to prevent air leak. The tube is connected to a water-seal device or Heimlich valve in stable patients without effusion. Complications include intercostal vessel bleeding, tube kinking or clogging, malposition, and re-expansion pulmonary edema, which requires supportive care.
Local anesthesia with 1% lidocaine with epinephrine (maximum 7 mg/kg up to 500 mg) is used for procedures, and procedural sedation may be considered in stable patients. Antibiotics are not indicated for clean procedures.
Admission is required for tension pneumothorax or any patient requiring chest tube placement. Stable patients with small pneumothoraces managed conservatively or with successful aspiration may be discharged with close follow-up at 24 hours and one week, including repeat chest radiographs. Patients must receive clear instructions to return immediately for recurrent chest pain or dyspnea. Persistent failure of lung re-expansion at one week warrants cardiothoracic surgery consultation.
Timely recognition and decompression of tension pneumothorax are critical to prevent rapid hemodynamic compromise. Proper tube placement and awareness of associated injuries, including mediastinal or esophageal pathology when pneumomediastinum is present, are essential to avoid complications.
